Results of a retrospective study of a racially diverse population demonstrated positive outcomes for patients with NSCLC who experience irAEs when treated with immune checkpoint inhibitors.

The median progression-free survival was 6.8 months, and the median overall survival was 19.1 months. Pegylated liposomal doxorubicin (PLD) has demonstrated safety and efficacy in patients with ...

A retrospective study revealed differences in metastasis patterns and treatment utilization by ethnicity among patients with breast cancer and brain metastasis.

All patients receiving surgery/radiotherapy alone or with chemotherapy had improvement or stability of alopecia with LDOM.

Among patients with early-stage malignant melanoma who underwent standard excision, the incidence of residual melanoma tumor cells in tissue from a wide local excision was low, at less than 5% of ...

The predictive model demonstrated an 8-year cumulative incidence of TKI failure in the training set of 10% in the low-risk group, 34% in the intermediate risk, and 69% in the high-risk. In the ...

Recent research bolsters the case that radiotherapy to treat primary endometrial cancer is associated with an increased risk ...

An analysis of the clinical utility of the Hematotox-Score demonstrated the tool is predictive of hematologic toxicity in patients undergoing CAR-T therapy, but is not predictive of mortality.

Targeted, culturally adapted clinical and public health interventions are needed to narrow disparities in cancer mortality,” researchers concluded.

HealthDay News — For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T ...

More research is needed to address barriers to therapeutic monitoring of prostate cancer patients on androgen deprivation therapy, according to researchers.

Neoadjuvant RT strongly recommended for stage II to III rectal cancer but can be omitted for those at lower risk for locoregional recurrence.